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Abstract
Background
Multiplex assays are increasingly applied to analyze multicomponent signatures of human
immune responses, including the dynamics of cytokine and chemokine production, in obser-
vational as well as interventional studies following treatment or vaccination. However, rela-
tively limited information is available on the performance of the different available multiplex
kits, and comparative evaluations addressing this important issue are lacking.
Study design
To fill this knowledge gap we performed a technical comparison of multiplex bead assays
from 4 manufacturers, each represented by 3 different lots, and with the assays performed
by 3 different laboratories. To cross compare kits directly, spiked samples, biological sam-
ples and a newly made reference standard were included in all assays. Analyses were per-
formed on 324 standard curves to allow for evaluation of the quality of the standard curves
and the subsequent interpretation of biological specimens.
Results
Manufacturer was the factor which contributed most to the observed variation whereas vari-
ation in lots, laboratory or type of detection reagent contributed minimally. Inclusion of a
common reference standard allowed us to overcome observed differences in cytokine and
chemokine levels between manufacturers.
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Conclusions
We strongly recommend using multiplex assays from the same manufacturer within a single
study and across studies that are likely to compare results in a quantitative manner. Incorpo-
ration of common reference standards, and application of the same analysis method in
assays can overcome many analytical biases and thus could bridge comparison of indepen-
dent immune profiling (e.g. vaccine immunogenicity) studies. With these recommendations
taken into account, the multiplex bead assays performed as described here are useful tools
in capturing complex human immune-signatures in observational and interventional studies.
Introduction
Multiplex bead assays are commonly used for monitoring of complex multicomponent signatures
of human immune responses in observational as well as interventional studies, such as treatment
or vaccination trials. Measurement of secreted inflammatory mediators is relevant to many fields
of study, including human infectious diseases, autoimmune diseases, cell signaling, neuroscience,
cardiovascular diseases and cancer. In addition, more reagents and assays are becoming available
for other species such as mice, porcines, canines, rats and non-human primates. These advances
will facilitate cross-species comparisons of multicomponent immune signatures.
There are many components of the host immune response that may contribute to these sig-
natures, including T-cells, B-cells, NK cells, neutrophils and monocytes. Multiple cytokines
and chemokines can be produced simultaneously and the magnitude and balance of these dif-
ferent mediators defines the functional response signature [1]]. Over the last decade various
commercially available multiplex suspension bead assays have been developed and gradually
improved towards more robust and user- friendly assays. For example, polystyrene beads have
been replaced with magnetic beads resulting in increased accuracy and reproducibility [2]].
The number of available analytes in a single assay has been expanded to approximately 40 cyto-
kines or chemokines. Because the demand for easy and robust multi-parameter assays is still
increasing multiple vendors have started to produce and market these assays. In human vacci-
nation studies, sample numbers and volumes are often limited, in particular when involving
young children, and frequently involve longitudinal sampling such that assays are preferred
that are high-throughput, able to handle small sample volumes and still provide multi-factorial
signature data. Current commercial multiplex bead assays can be performed on as little as 25–
50 μl of culture supernatant from stimulated PBMC cultures, (diluted) venous blood or serum/
plasma, and enable analysis of a large number of analytes. Another major advantage of these
assays is that samples can be collected and stored, thus allowing serial measurements of sam-
ples from individuals in a single assay, thereby limiting inter-assay variation and thus optimis-
ing detection of possibly subtle perturbations in cytokines, chemokines and other secreted
analytes over time [3, 4]. In the past few years many studies have been performed in which
multiplex assays were tested for accuracy and reproducibility by including spiked samples or
WHO standards, and compared to single analyte assays like ELISA and ELISpot [5–8]. More-
over their performance was evaluated in combination with optimized stimulation protocols
for PBMC samples [9]. Even though multiplex bead assays cannot identify the cellular source
of any biomarker measured but the total concentration of a cytokine or chemokine in a given
sample, they provide powerful tools for multicomponent analysis of immunologic responses,
which can guide further in-depth exploratory research to define the potential cellular sources
and cellular interactions involved.
Multiplex bead arrays benefit from common reference standard
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For each of the three major infectious diseases, TB, HIV and malaria, human immune
responses induced by vaccination, in particular new experimental vaccines under evaluation
are complex and multifactorial. Therefore, monitoring vaccine-induced changes over time
needs to be broad and include a variety of cytokines and chemokines, rather than preselected
single markers. In malaria it has been shown that different stages of parasitic infection involve
different cytokine patterns, and that the balance of the cytokines determines the control of
infection and disease outcome [10]. In BCG vaccination studies, complex cytokine profiles
such as those obtained by multiplex bead assays proved to be valuable tools to discriminate
vaccine induced responses across different continents [11, 12]. For each of these three diseases,
field studies and trials are complicated because of large group sizes, long follow-up times and
frequently poor local infrastructure in affected endemic areas. In order to achieve sufficient
power, studies are frequently run at multiple sites.
To search for immune correlates of protection, it would be even more informative if it were
possible to perform head-to-head comparisons of responses induced by different vaccine can-
didates in relation to clinical outcome, e.g. protection or disease. At the moment, the best
proximate is to harmonize vaccine study design as well as immunological monitoring to the
highest degree possible. Harmonization of assays such as the multiplex bead assay would allow
an unique opportunity to conduct comparative analysis of vaccine induced immune responses
over sites and over different vaccination trials. However, to run harmonization optimally it is
critical to identify the factors that are responsible for variation within an assay. Therefore, we
have here conducted a technical comparative study of multiplex cytokine and chemokine
assays between 3 laboratories, using the kits from 4 manufacturers and 3 different lots, testing
the same samples, including spiked samples, biological samples and a newly made reference
standard as key reagents to understand the assay variation and interdependence. We then
determined the major components responsible for variation based on advanced unbiased sta-
tistical methods. The results described below provide recommendations for optimal use of
multiplex bead assays across different laboratories and studies.
The EURIPRED consortium aimed to identify the major factors in these assays that might
influence the results and limit cross comparability between studies. The aim was also to
develop solutions and reagents to overcome variability to enhance cross study comparative
data analysis and evaluation, without real head-to-head comparisons, thereby accelerating the
development of vaccines for globally important pathogens including TB, malaria and HIV.
Results
Standard curve analysis as stage-gates for each analyte
Within the EC FP7 EURIPRED consortium (www.EURIPRED.eu) 18 cytokines and chemo-
kines were selected commercially available multiplex bead assays were ordered for these ana-
lytes. Reagents/ kits were purchased from 3 different lots (batches) from each of the 4 different
selected manufacturers (Bio-Rad, Millipore, Ebiosciences, R&D systems) (Fig 1A). Each man-
ufacturer provided three sets of kits from one lot, which were then sent to the 3 participating
laboratories (labs) for data comparison using the same lot when tested by each of the 3 labs
(Fig 1A). In addition, 2 more lots from each manufacturer were tested. Each lab tested addi-
tional lots from a different manufacturer, to minimize bias towards possibly confounding lab
specific parameters (Fig 1A). In addition, a third party universal detection reagent was
included as an extra condition in all assays in all labs, in order to be able to compare all kits,
using identical fluorescent detection reagents. Finally, all labs tested exactly the same spiked
samples, reference standard and biological samples, with all kits and lots. In total 20 kits were
tested in this study allowing analysis of 324 standard curves.
Multiplex bead arrays benefit from common reference standard
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Fig 1. Description of standard curves by logistic function. (A) A schematic overview of all the variables tested is shown in Fig 1A. 17 Analytes
(CCL2/MCP-1, CCL3/MIP-1 α, CCL4/MIP-1β, CXCL10/IP-10, GM-CSF, IFN-γ, IL-1 alpha, IL-1β, IL-10, IL-13, IL-17, IL-18, IL-1ra/IL-1F3, IL-2,
IL-5, IL-8, TNF-α) out of the original 18 analytes of interest were assessed using kits from 4 different manufacturers; all the kits were tested in 3
independent laboratories. Each kit was tested from 3 different lot numbers, 1 lot was tested in all 3 laboratories whereas 2 additional lots were tested
in a single laboratory (Lab).(B) Representative graph of the fluorescence vs the concentration of the standard curve shown in red. The curve is
described by the logistic function f(x) = A + B/(1 + e−C(x-D)) where f(x) and x represents respectively the log transformed values of the fluorescence
and the concentration. Here A is the intercept, A+B = maximum value of the curve, C is the slope of the curve, e is the natural logarithm base and D
Multiplex bead arrays benefit from common reference standard
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All data files from all manufacturers’ specific standard curves were collected and data were
analyzed using a logistic function to describe the main characteristics of the standard curves.
All data were analyzed using the same methodology, irrespective of instructions by the manu-
facturer. IL-12-p40 was excluded for comparative analyses as reagents for this cytokine were
only available from one manufacturer. The logistic function for calculating the standard curve
(red) showed a near perfect fit with a R2 of 0.999 to the actual data points measured (in blue)
illustrated in Fig 1B, for TNF-α. Utilizing this logistic function the standard curves were
described based on intercept A, maximum value A+B, slope C and sigmoid point D. The devi-
ation of the measured fluorescence value versus the predicted value for the curve, was also cal-
culated and plotted as residual value (right panel, Fig 1B). Since TNF-α has an excellent curve
fit residual values are minimal.
All 324 manufacturers’ specific standard curves were analyzed for all 4 curve fitting parame-
ters and the frequency distributions were plotted (S1A Fig). The 5–95% confidence intervals
(CI) were used to classify the results (in Fig 1D). The parameters A, B, C and D were important
indicators for the quality of the standard curves, in addition to the typically used R2. Plotting
these parameters for frequency distribution for assays from the individual manufacturers
resulted in unique profiles (S1B Fig). In particular, the slope of the standard curves for manu-
facturers III and IV and the sigmoid point for assays using reagents from manufacturer III
deviated from the mean of the total curves analyzed. Each manufacturer provided its own stan-
dard, and parameters A to D allowed us to evaluate the quality of these curves and therefore
the plausibility of the interpolated unknowns.
Fig 1C illustrates manufacturers’ specific standard curves with excellent R2 values for curve
fitting, 0.998 for GM-CSF and IL-10 and 1.000 for CCL3, but these curves were nevertheless
not ideal for interpolation and subsequent interpretation of test samples. The GM-CSF plot
shows a value for intercept A that exceeds the 5–95% CI, indicating a high background value
and a flat first part of the curve, making it difficult to interpret data in the lower range of the
standard curve and resulting in a small dynamic range for interpolating data. For CCL3 and
IL-10, both curves have a slope value outside the 5–95% CI. In case of CCL3 the value for the
slope is high, which results in a very accurate concentration but a small dynamic range. For IL-
10 the slope value C is low which suggests a limited accuracy in quantifying the unknown
concentrations.
Evaluation of the quality of the standard curves was based on the score for each of the curve
fit parameters for every analyte in each of the participating labs as shown in Fig 1D. Green
indicates that the parameter fits within the 5–95% CI and red indicates failure to meet these
criteria for that specific parameter. A total of 9.2% of the curve fitting parameters are outside
the confidence interval criteria, and these were distributed over different kits and different
labs. Only the assays for CCL3 from manufacturer I and for IL-5 and IL-8 from manufacturer
III performed poorly in all 3 labs for the parameters C (slope) and D (sigmoid point). Overall
the differences between standard curves, labs and lots were minimal.
is the value of x at the sigmoid point shown here in red. The blue line shows the actual measured values. The residual vs the predicted fluorescence
value is displayed in the insert. The predicted fluorescence value of each standard sample is calculated by the logistic function. The residual values
represent the deviation of the measured fluorescence values from the predicted fluorescence values at all given concentrations.(C) Representative
standard curves, originating from 2 labs, 2 manufacturers and 3 lots, are plotted for which the constant A (GM-CSF) and C (CCL3 and IL-10) are
not within the 5–95% CI based on all 324 standard curves measured. (D)Summary of all standard curves analyzed at the 3 different labs with the
same lot of reagents where green represents curve fitting for parameters A, B, C and D within the 5–95% CI and red indicates the parameters that
do not meet the 5–95% CI criteria based on frequency distributions of 324 standard curves. Analytes that were not provided by the manufacturer in
that specific assay are shown in white.(E)Correlation between analysis methods is plotted for each manufacturer. On the X-axis the values for the
spiked samples of 500 and 1500 pg/ml as calculated by the estimation method according to Levenberg-Marquardt are represented against those
calculated by the Bioplex software on the Y-axis.
https://doi.org/10.1371/journal.pone.0201205.g001
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Furthermore, we analyzed spiked samples with the widely used and commercially available
BioPlex Manager software and compared this to the logistic function by the estimation method
of Levenberg-Marquardt. Fig 1E shows the correlation of both analysis methods for each of the
manufacturers. Samples on the diagonal line were not influenced by the analysis method, but
as can be seen for all manufacturers, there were samples that deviated to either the horizontal
or the vertical axes. For manufacturer IV, all samples were either underrated by the BioPlex
software or overrated by the logistic function whereas this was only the case for individual
measurements with the other manufacturers. It is also clear that manufacturer I and III dem-
onstrated the best correlation in this analysis. Thus, it is important to harmonize also on the
analysis platform to be used when cross-comparing data.
An unbiased analysis identifies manufacturer as a major factor
contributing to variation
Spiked samples were generated at the National Institute for Biological Standards and Controls,
UK (NIBSC) by combining all 18 chemokines and cytokines at a concentration of either 500
pg/ml or 1500 pg/ml each. These concentrations were chosen to be in the range of interest of
the biological samples based on previous experience, and are expected to fall in the linear part
of the standard curves for most analytes.
Fig 2A shows an unbiased Variance Component Estimation. This variance analysis weighs
the contribution to total variance observed for every component of the assay independently.
For all cytokines and chemokines measured in the spiked sample with a reference value of 500
pg/ml or 1500 pg/ml the boxes show the median and the 25–75% quantile of all data points,
irrespective of lot, lab, manufacturer or the streptavidin-PE detection reagent (‘label’) used to
detect the biotinylated detection antibodies (n = 40 per analyte; n = 20 for the manufacturer
detection reagent plus another 20 data points for the universal detection reagent), with the
whiskers showing the minimum and maximum values and the dots the extreme outliers above
the 1.5 times interquartile range. Box-sizes are a measure of the total variance within the ana-
lyte, small boxes thus indicate that all kits yielded virtually the same results. Many analytes did
not yield the expected concentrations and some deviated more than 2-fold. When averaged,
only 6 analytes differed less than 25% for the spiked 500 pg/ml concentration, and 7 analytes
for the spiked 1500 pg/ml concentration. All other analytes were more than 50% higher or
lower than expected. All manufacturers performed equally poorly in this respect. For CCL4,
CXCL10, IFNγ, IL-2, IL-10 and IL-17 the boxes for the 500 pg/ml spiked sample were larger
than for the 1500 pg/ml spiked sample. This indicates that the 1500 pg/ml sample fitted the lin-
ear part of the standard curves better than the 500 pg/ml sample. For IL-1α and IL-1β the
opposite is true, spiked samples with a concentration of 500 pg/ml gave less variation.
Fig 2B shows the contribution of each of the components (lot, lab, detection label or manu-
facturer) as part of the total variance. For nearly all analytes the manufacturer appears to be
the largest parameter determining the overall variance. The other contributors to variance
-lab, detection label and lot- are more subtle and their contribution to the total variance
depends on the specific analyte. Overall the total variance for most analytes was limited and
the different lots contributed only to a small proportion of the observed total variance. Strepta-
vidin PE supplied by the manufacturer or universal streptavidin PE resulted in very similar val-
ues as can also be seen in the direct comparison in S2 Fig. If only data with the universal
detection reagent are considered (Fig 2C), the total variance pattern hardly differs from that
shown in Fig 2B, indicating that some factors other than the detection reagent determines vari-
ation between manufacturers. For the few analytes with very low total variances, such as IL-5,
IL-13 and IL-18, the main component was not manufacturer but lab. Next to manufacturer,
Multiplex bead arrays benefit from common reference standard
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the remaining variation, e.g. between labs, then begins to have a relatively larger impact on the
results. This can be seen in Fig 2B and 2C and also in Fig 2D, where we show the actual raw
data that were used in the variance analysis.
In Fig 2D–2F, we plotted the different components of manufacturer, lab, and detection
labels per analyte respectively. For some analytes, such as CCL4, CXCL10, IL-1α, IL-17 or
TNF-α, one manufacturer was clearly different from the other 3, whereas for most analytes val-
ues were more scattered across the manufacturers. For the analytes that resulted in very small
total variances, e.g. IL-5, IL-8, IL-13 and IL-18, the variance remained mainly explained by the
lab-to-lab variation (Fig 2E), with minimal contributions of the manufacturer component. For
CCL4, IL-1β and IL-2, that showed large variations between manufacturers, the lab-to-lab con-
tribution to the overall variation was minimal. Finally, for all analytes the variation associated
with the detection label, streptavidin PE, was marginal (Fig 2F).
Results from biological samples are comparable within different multiplex
manufacturers
Biologically relevant samples covering a wide range of stimulation induced responses were
generated as described in the Materials and Methods. Supernatants were shared between labs
and tested by all kits allocated to each particular lab.
Radar or spider plots were constructed to visualize the results from these samples in Fig 3.
Specific stimuli are indicated in the corners of the plots, connecting lines are drawn between
results obtained with the same kit, and each manufacturer is indicated by a different color.
Using these plots, samples can be ordered or ranked based on the concentrations of analytes
measured within each kit. If all lines follow the same pattern for a given analyte, the samples
will give the same relative results even if the different samples do not have the same absolute
concentrations. By contrast, crossing lines indicate qualitatively different types of responses
for that particular analyte in those samples, suggesting that the ranking of these results is not
comparable between the different manufacturers or studies. In general, most lines followed
similar patterns and therefore, the relative (or ranked) response measured in these biological
samples was similar (Fig 3), with the exception of an occasional crossing of lines at higher con-
centrations of analytes e.g. CCL2, IL-1ra or IL-8.
A reference standard allows direct data comparisons
As an alternative to ranking cytokines and chemokines across biological samples, data can
also be plotted as cytokine and chemokine concentration per stimulation. Fig 4A represents
spider plots for each of the stimulation conditions comparing the different cytokines and
Fig 2. The commercial kit used is the main contributor of variance. (A)Left panel shows the concentration measured for
all cytokines and chemokines using the spiked sample 500 pg/ml and the right part of the panel shows the results for
spiked sample at 1500 pg/ml. Each box represents 40 data points. The line represents the expected concentration of each
analyte. Boxes indicate the median and 25–75 percentile of data with whiskers at 1.5 times the interquartile range and dots
indicating the extreme outliers above the 1.5 times interquartile range.(B)The bar graphs depict the contribution to the
total variance of the different components, lot (white), detection label (dark grey), lab (light grey) and manufacturer
(black) for the spiked sample 500 pg/ml on the left and spiked sample 1500 pg/ml on the right. (C) Same variance analysis
as in B but with the universal PE detection label (D) The panel represents the 10 actual data-points for each analyte
measured by the 3 labs for each of the manufacturers, I-IV from left to right, and all 3 lots and 2 detection labels. The
dotted line indicates the reference value of 500 pg/ml. (E) The panel represents the data for the 500pg/ml spiked sample for
each analyte over the different labs, for the same lot. The first box refers to lab 1, second to lab 2, third to lab 3 (total data-
points for analysis for each lab n = 8). (F) Data for the variable detection label is plotted, the first box for each analyte
indicates detection Streptavidin PE from the manufacturer (M) and the second box indicates the universal Streptavidin PE
(U). Results for each analyte are analyzed for the 3 labs, 4 manufacturers and 3 kit lots (n = 20). All data points originate
from the measurements of the 500 pg/ml spiked sample.
https://doi.org/10.1371/journal.pone.0201205.g002
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chemokines. Depending on the kit selected for the analysis, the results differ, and the relative
ranking of cytokine and chemokine responses was completely altered. Since supernatants were
identical, this is due to the variation in cytokine and chemokine concentrations measured with
different kits (Fig 4A).
These variations could reflect truly different measurements but may also be the result of dif-
ferences in data analysis methodology and extrapolation of values between the manufacturers.
To distinguish between these two possibilities, we decided to assess whether variation in the
observed concentrations between the different manufacturers could result from differences in
Fig 3. Ranking of biological samples is similar using kits from the different manufacturers. For each analyte and biological sample the data
obtained with kits from the different manufacturers I (green), II (red), III (blue) and IV (pink) was plotted in a radar or spider plot with the stimuli at
the corners of the plot. The geometric mean of all data-points (n = 5) for results from the different labs and kit lots is shown per sample using the
manufacturer’s standard values and detection label. Results above the standard curve were set at 10 000 pg/ml.
https://doi.org/10.1371/journal.pone.0201205.g003
Multiplex bead arrays benefit from common reference standard
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Fig 4. Common reference standard improved comparability for biological samples. (A) The results for the total cytokine/chemokine levels measured in
the biological samples was plotted as geometric mean (n = 5) for the different labs and for the different lots. The kits from different manufacturers are
shown in green (I), red (II), blue (III) and pink (IV) and data was related to the manufacturer’s standard values.(B) Results for the total cytokine/
chemokine levels measured in the biological samples after re-analysis against the common reference standard curve.
https://doi.org/10.1371/journal.pone.0201205.g004
Multiplex bead arrays benefit from common reference standard
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the standard curves provided with each of the kits. An external, reference standard, based on
serial dilutions from a spiked sample at 10,000 pg/ml generated at NIBSC, was incorporated in
all assays, permitting calculation of unknown concentrations based on this reference standard.
Concentrations in the biological samples were then calculated relative to this reference stan-
dard (Fig 4B). The reference standard equalized the concentrations and normalized the data to
comparable patterns over the different analytes, between the different kits. These results dem-
onstrate that incorporation of a reference standard overcame differences between kits obtained
from manufacturers, thereby facilitating comparative analyses.
Discussion
In this study we present the results of a technical comparative evaluation of multiplex cytokine
and chemokine bead assays from 4 different manufacturers, with 3 lots from each manufac-
turer, and 2 detection reagents performed by 3 independent laboratories. These multiplex
assays calculate analyte concentrations using standard curves. Standard curves must be evalu-
ated by preset criteria for intercept, maximum value, slope and sigmoid point. Our variance
component estimation identified the major component of variance as being the manufacturer,
and that this could be largely overcome by inclusion of a common reference standard. Our rec-
ommendations for optimal use of multiplex bead assays across different laboratories and stud-
ies should enhance cross study comparative data analysis and evaluation, which should help
accelerate the development of vaccines for globally important pathogens such as TB, HIV and
malaria.
In head-to-head comparisons attention should be paid to harmonize not only the multiplex
read out, but in addition preparation of samples and stimulations assays should be carefully
harmonized. Synchronization between different studies and laboratories should include blood
collection tubes, processing of whole blood or PBMCs. Furthermore, standard operation pro-
cedures for stimulation should be in place, describing cell numbers, media and type and con-
centration of stimulation reagents. Harmonized stimulation procedures in combination with
the optimized multiplex bead array protocol should permit comparative analysis of cytokines
responses between studies.
Inter- and extrapolation of test sample values are typically based on the standard curve,
therefore understanding the characteristics and limitations of standard curves is of major
importance, and should be incorporated in all data analyses and validation strategies. Standard
curves were described here by their slope, intercept and sigmoid point regardless of the maxi-
mum concentration that was included in the standard curve. Maximum concentrations varied
between manufacturers, affecting the detection range of individual kits. A standard curve with
a small concentration range but a large fluorescence detection window may reflect a more
accurate assay, but for sample screening purposes larger concentration ranges are preferred,
particularly as samples are commonly used at a single dilution. As shown in Fig 1C, slopes and
intercepts have great impact on the dynamic range, sensitivity and accuracy that can be
achieved with a given assay. Standard curves should be assessed before data is inter- or extrap-
olated, and if one or more characteristics fail to fall within the 5–95% CI criteria, data should
be interpreted with caution or discarded. Concentrations resulting from suboptimal standard
curves can only be used to classify the measurements as being low, medium or high but no
actual concentration can be calculated for these samples. Furthermore as shown in Fig 1E, the
analysis method matters and we would recommend using the same analysis method especially
when evaluating across different studies.
The variation observed in this study was largely the result of using kits from different manu-
facturers, while kit lots and the labs performing the assays contributed only a minor part of the
Multiplex bead arrays benefit from common reference standard
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variation. Also the universal detection reagent did not reduce variation significantly and was
not a critical factor. Surprisingly, detection of spiked samples with fixed, known concentra-
tions resulted in a large range of concentrations using the different kits, which deviated consid-
erably from the calculated input amount. Amounts in the spiked samples were calculated
against the standard curves provided with the kits. Formally variations in the amount of pro-
tein in either spiked sample or standard from the kit cannot be excluded. However, the large
variation in values detected in the spiked samples between kits from different manufacturers
may be caused by the fact that each manufacturer uses its own monoclonal or polyclonal anti-
body pair to detect the analyte, which may differ in affinity. Detailed information on antibod-
ies in the kits is typically not disclosed by the manufacturers but it is likely that this is one of
the major factors leading to the differences between the kits [13–15]. Although the absolute
concentrations in the stimulated samples were different, the relative distributions were similar,
and differences were abrogated by the use of a common reference standard. This suggests that
the standards employed by the different manufacturers are also different and that these make a
major contribution to the variations observed.
Detection of the spiked sample depends on the standard curve characteristics, in particular
the maximum value measured in the standard curve. Some kits included a large working range
from 3–10,000 pg/ml where the spiked samples fitted the ideal linear part of the curve per-
fectly, whereas others had tenfold lower ranges, from 3–1000 pg/ml. Hence, the spiked sample
might be on the higher or lower end of the sigmoid area of the curve where the sensitivity and
accuracy are less optimal. However, spiked samples were tested at 2 concentrations, at least
one of which was expected to be in the linear part of the standard curve. Biological samples are
expected to yield most reliable and reproducible results when in the linear part of the standard
curve, and therefore in general, standard curves with the longest linear ranges will give most
reproducible results. Thus replacing the kit standard with an universal standard could in par-
ticular enhance the results for analytes that have short-range standard curves in the original
kits.
Besides the above mentioned manufacturer’s specific differences, the use of buffers and
matrix diluents differs per assay. It has been reported by Jager et al [16] that proteins other
than antibodies can interfere with the assay. Since we performed the assays according to man-
ufacturer’s instructions we could not investigate potential effects of buffers and matrix dilu-
ents. However, if these would have been a major factor we would have expected all results
from a particular manufacturer to deviate systematically in the same direction, rather than
analyte specific differences as observed here. In addition, data extrapolation with the common
reference standard would not have normalized the data as well as it did. Furthermore we did
not take into account the time span that could be present between experiments in real-life, as
our assays were performed within the limited timeframe of six months. Generally in clinical
studies the evaluation of immune responses will only be initiated after the sample collection is
completed, and by analyzing all samples per individual in one occasion, testing all samples
within a limited time span and using one assay lot. However, if multiple assays need to be per-
formed over longer periods of time with different kit lots, we believe there is an added value of
including a reference standard or spiked samples.
In vaccine development and immune monitoring studies, many have exploited the advan-
tages of the multiplex bead assay as a versatile screening tool suitable for small sample volumes
and large sample numbers [2, 11, 12, 17]. At the same time, many laboratories have also
encountered inconsistencies in the determined absolute values, discrepancies between technical
specifications and the actual performance, differences in sample preparations and differences in
the methodology for executing the various assays [2, 6, 14, 18]. Breen et al.[15]reported that the
multiplex assay may not be sufficiently reproducible for repeated determination of absolute
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cytokine concentrations but may be very useful in longitudinal studies where relative values are
more interesting. However, we suggest that the inclusion of a common reference standard
could rectify this. To better comprehend the observed differences in absolute values Khan et al.
[6] have compared the absolute concentrations (pg/ml) with the complementary international
units (IU), but the differences remained. Nechansky et al.[5] included WHO standards in their
assays displaying an overestimation of the results based on the underestimation of the standard
curves in the kits compared to these WHO standards. These differences in absolute values of
the multiplex bead assays remain problematic in head-to-head comparisons when different
assays are used. Based on our conclusions that the manufacturer is the key component responsi-
ble for variance, and that the lab performing the assay and the kit lot are the minor variants in
the assays’ variability. We suggest that multisite comparisons are feasible as long as longitudinal
studies are measured in the same assay with the same kit from the same manufacturer, and
when external reference standards are included.
In this study, we conducted a thorough analysis on the characteristics and comparability of
the same highly standardized commercially available multiplex beads assays over 3 different
labs, 3 different lots and with kits from 4 different manufacturers. To compare as many possi-
ble conditions that will be of greatest value to the fields of immune profiling, we undertook
costly test conditions with duplicate reference standards, which might not be feasible in real
life. However, we suggest that adding a reference standard, or one or more spiked samples are
important for data comparisons when analyzing clinical trials and larger cohorts in which
such extra costs are relatively marginal and quantitative outcomes extremely valuable. We sug-
gest that the kit for a particular manufacturer itself is not critical for standardising across the
field. Our data show that the use of our proposed common standard is capable of overcoming
the differences introduced by the choice of manufacturer. Furthermore it may not be possible
to decide unambiguously for each research group and research question which would be the
best manufacturer since this also depends on the sample source to be measured, e.g. sera or
plasma, whole blood or PBMC culture supernatants and the analytes of interest. The sample
source will also influence the expected cytokine and chemokine levels, and this impacts the
choice of manufacturer and kit.
The range of the reference standard curve, replacement of the manufacturer’s standards,
and the number of replicates used can be further discussed, and assays can be custom-made to
fit specific needs and study design. Once these decisions are made we recommend that kits
from one manufacturer are used for each separate study analysis, with common reference stan-
dards, one analysis method is applied and that standard curves are critically judged per cyto-
kine before extrapolation of the data. This will allow the maximum information to be obtained
on the biomarkers being analyzed and enable reproducible and robust bio-signatures to be
identified. Multiplex bead arrays are thus a very useful tool to monitor human immune
responses over time, such as during disease or following vaccination.
Materials and methods
Cytokine and chemokine multiplex beads assays
The following cytokines and chemokines were selected based on solicited interests of research-
ers in the field of poverty related diseases, covering a wide array of Th1, Th2, Th17 as well as
monocytic responses; CCL2/MCP-1, CCL3/MIP-1 α, CCL4/MIP-1β, CXCL10/IP-10, GM-
CSF, IFN-γ, IL-1 α, IL-1β, IL-10, IL-12 p40, IL-13, IL-17, IL-18, IL-1ra/IL-1F3, IL-2, IL-5, IL-8,
TNF-α.
All multiplex magnetic bead assays were performed according to manufacturer’s protocols.
Assays included in this study were (I) Biorad (Bio-Plex pro Human Cytokine 27-plex assay,
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Veenendaal, The Netherlands; 15 analytes were analyzed per kit), (II) Ebioscience (Procarta-
Plex human Cytokine & Chemokine panel 1A, 34-plex, Hatfield, United Kingdom; 17 analytes
were analyzed per kit), (III) Merck Millipore (Milliplex Human Cytokine/chemokine magnetic
bead premixed 29-plex kit, Watford, United Kingdom; 17 analytes were analyzed per kit) and
(IV) R&D systems (Human Magnetic Luminex Screening assay 16-plex, Biotechne, Abingdon,
United Kingdom; 16 analytes were analyzed per kit). Some manufacturers supplied quality
control samples with the kits, but since not all kits provided those and they only indicated an
expected range, they were not included. Manufacturer specific standards and the common ref-
erence standards were run in duplicate, spiked samples and biological samples were run as sin-
gle measurements. Detection of samples was performed with the Streptavidin-PE detection
label supplied by the manufacturer and a duplicate set of samples was analyzed with a universal
Streptavidin-PE (Becton Dickinson, Eerbodemgem, Belgium). All laboratories used the Bio-
Plex 100 system for data acquisition.
Preparation of spiked samples and reference standard
Eighteen cytokines were selected for the preparation of spiked samples and reference standard
to cover a broad range of immunological responses. Out of 18 cytokines; 5 cytokines were
WHO International Standard from NIBSC—GM-CSF (Cat. No. 88/646), IL-1α (Cat. No. 86/
632), IL-1β (Cat. No. 86/680), IL-8 (Cat. No. 89/520) and TNF-α (Cat. No. 88/786); 5 cytokines
were WHO reference reagents from NIBSC–IL-10 (Cat. No. 93/722), IL-13 (Cat. No. 94/622),
IL-17 (Cat. No. 01/420), IL-18 (Cat. No. 03/200) and IL-5 (Cat. No. 90/586), and IL-1ra/IL-1F3
(Cat. No. 92/644) from NIBSC is a non-WHO reference reagents. The rest of the 7 cytokines
were obtained from commercial suppliers–IFN-γ (Cat. No. 14-8319-80) and CCL4 (Cat. No.
14-8938-80) from Ebioscience; IL-2 (Cat. No. 11011456001) from Sigma; CCL2/MCP-1 (Cat.
No. 279-MC-010), hIL-12p40 (Cat. No. MAB6091-100) and CXCL10 (Cat. No. 266-IP) from
R&D systems; CCL3 (Cat. No. 582802) from Biolegend. For preparing reference standard, all 18
cytokines were reconstituted as per instruction for use or manufacturers’ recommendations,
further diluted with PBS+0.1% BSA and mixed to obtain final concentration of 10,000pg/ml of
each analyte at NIBSC. For preparing spiked samples, 18 cytokines were mixed and diluted with
PBS+0.1%BSA to obtain 500pg/ml and 1500pg/ml of each analyte.
Preparation of biological samples
For preparation of the biological samples PBMC were isolated using Ficoll density centrifuga-
tion (LUMC Pharmacy, Leiden, the Netherlands) from buffy coats of healthy blood bank
donors (Sanquin, Amsterdam, The Netherlands). PBMCs were cultured at 6x106 cells/ml in
T75 flasks in RPMI supplemented with glutamine (Gibco, Thermo Fisher Scientific, Bleiswijk,
the Netherlands) and 10% FBS (Hyclone, GE Healthcare Life Sciences, Eindhoven, the Nether-
lands), in the presence of the following stimuli: PMA (50 ng/ml) and ionomycin (250 ng/ml)
(both Sigma Aldrich, Zwijndrecht, the Netherlands) for 24 hours, PHA (5μg/ml, Remel,
Thermo Fisher Scientific, Bleiswijk, The Netherlands) for 3 days and SEB (2 μg/ml, Toxin
Technology, Sarasota, FL, USA), PPD for in vitro use (5 μg/ml, Serum Statens Institute,
Copenhagen, Denmark) and Tetanus Toxoid (RIVM, The Netherlands) for 5 days. A mixed
lymphocyte reaction sample was generated by mixing PBMCs from two random donors (1:1)
and culturing them for 6 days at a concentration of 3x106 cells/ml from each donor. At the end
of the cultures, supernatants were harvested, aliquoted and lyophilized for distribution and use
in the multiplex bead assays. No unstimulated control supernatants were included and cyto-
kine and chemokine levels of the biological samples were thus not background corrected.
The PMA/ionomycin, PHA, SEB and MLR stimulated supernatants were diluted 5x before
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measurements. All labs reconstituted and diluted the lyophilized samples in the same way and
tested the same dilutions.
Statistical analysis
All data were analyzed by SPSS (IBM statistics v23) where the estimation method of Leven-
berg-Marquardt was used with the logistic formula f(x) = A + B/(1 + e−C(x-D)) to perform the
non-linear regressions describing the standard curves. In total 324 out of 325 standard curves
were analyzed originating from 20 kits with 15 to 17 analytes per kit as stated by the descrip-
tion of the multiplex bead assays. One standard curve was excluded due to a technical issue.
All standard curves included 6 serial dilution points in duplicate. Besides the logistic function
BioPlex Manager software (v6.1) was used for correlation of both analysis methods. Variance
componence analysis [19] was performed per cytokine with variance components for manu-
facturer, lot, lab and detection label using R, a language and environment for statistical com-
puting (R Foundation for Statistical Computing; 2014, Vienna, Austria) and the script
included in the S1 File. The box and whisker plots indicate the 25–75% quantile, with the
median at 50% and the lower whisker equal to the smallest observation greater than or equal to
the lower hinge -1.5IQR. The upper whisker equals the largest observation less than or equal
to upper hinge + 1.5  IQR. Outliers are plotted as dots. Data was plotted using Graphpad
Prism v7.0 and Microsoft Excel 2010.
Supporting information
S1 Fig. Frequency distribution analysis of the curve fit parameters. (A) The frequency dis-
tribution and statistics for the parameters A (intercept), B (maximum), C (slope) and D (sig-
moid point) of all 324 standard curves analyzed. (B) Breakdown of the different parameters A,
B, C and D over the different manufacturer’s (I-IV) is shown as frequency analyses with dotted
lines at median and 5–95% CI.
(PPTX)
S2 Fig. Comparison of the component ‘detection label’ does not show significant differ-
ences in variance. For the spiked samples (500 and 1500 pg/ml) the variance of the manufac-
turer label (M) were compared to that using the universal detection label (U). The left graph
shows the data for spiked samples at 500 pg/ml and the right graph for the 1500 pg/ml concen-
tration.
(PPTX)
S1 File. R script.
(DOCX)
S2 File. Raw data.
(XLSX)
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